Europe’s SEP bombshell; Huawei and Verizon settle patent fight; Protecting AI via the EPO; Ericsson royalties jump; Arthrex - the good, bad and ugly; plus much more

Europe’s SEP bombshell; Huawei and Verizon settle patent fight; Protecting AI via the EPO; Ericsson royalties jump; Arthrex - the good, bad and ugly; plus much more

Everything we covered on IAM over the last seven days – and all you need to know from the global IP market to set yourself up for the start of another busy week

The Long Read

The patent pool model has long been recognised as an effective means for providing access to technology and fuelling innovation. However, argue Sullivan & Cromwell’s Garrard R Beeney and Renata B Hesse, its evolution has also lent collaborations a fiercely pro-competitive edge. Read more here

MONDAY 12 July

The EPO is ready and waiting for AI-related patent applications, but that doesn’t mean it will make the path to getting protection an easy one. Read more here

In a very challenging climate, Shenzhen-based Tencent is turning to a lawyer and executive with ample IP experience as its top global policy man. Read more here

A Biden Administration executive order widely seen as an attack on the power of Big Tech hands Silicon Valley's titans all they could have hoped for when it comes to SEPs and FRAND. Read more here


Three days into an EDTX jury trial, Huawei and Verizon have ended a patent dispute that put the Chinese company’s licensing ambitions under a microscope at the peak of the US-China trade war. Read more here

The European Commission has initiated a process that could end in legislation which will effectively decide the outcome of the global debate around SEPs and FRAND. Read more here

China wants to curb the influence of major tech players and ensure that innovation – and data – stay at home. It may hurt business growth, but it will not slow R&D. Read more here


A Maxell patent acquisition from Hisense shows that the Japanese company is doubling down on its IP monetisation strategy. Read more here

By providing an extra layer of IPR decision scrutiny, changes following the high-profile Supreme Court Arthrex decision are likely to be a boon for biopharma patent owners. Read more here


IPValue has acquired over 1,200 patents and applications from Mitsubishi in a deal that includes “substantially all” of the Japanese company’s rights relating to its display business. Read more here

Following years of lobbying, a trade deal with the US and more than 12 months’ legislative and regulatory preparation, the Chinese patent linkage system has finally got off the ground. Read more here

When pursuing NFT patent protection at the USPTO, key concerns include eligibility, directing claims to a potentially infringing and identifiable entity, and broadening search efforts. Read more here

FRIDAY 16 July

A Huawei-granted licence that will extend 4G protection to Volkswagen’s vehicles hints at how the auto patent licensing landscape might evolve. Read more here

Ericsson’s licensing income jumped in the second quarter on the back of the licensing deal it agreed with Samsung earlier this year. Read more here

The Biden Administration has abandoned Trump-era proposals to rule out patent suspension under the Bayh-Dole Act. Read more here


The long-awaited SCOTUS Arthrex decision does not provide a workable solution to the problem at the heart of the case, while the USPTO’s plans to implement it are deeply flawed. That spells trouble. Read more here

Unlock unlimited access to all IAM content